Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

@inproceedings{Berkowitz2015SafetyAI,
  title={Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study},
  author={Elchonon M. Berkowitz and Graeme Moyle and Hans-J{\"u}rgen Stellbrink and Dirk Schuermann and Stephen Kegg and Matthias Stoll and Mohamed El Idrissi and Lidia Oostvogels and Thomas C. Heineman and Norbert H Brockmeyer and Edwin Dejesus and Stefan Esser and Trevor Hawkins and Jacob P. Lalezari and Chloe M. Orkin and Stefan Schneider},
  booktitle={The Journal of infectious diseases},
  year={2015}
}
BACKGROUND Human immunodeficiency virus (HIV)-infected individuals are at increased risk of herpes zoster (HZ), even in the antiretroviral therapy (ART) era. Because concerns exist about the use of live-attenuated vaccines in immunocompromised individuals, a subunit vaccine may be an appropriate alternative. METHODS This phase 1/2, randomized, placebo-controlled study evaluated the immunogenicity and safety of an investigational HZ subunit vaccine (HZ/su). Three cohorts of HIV-infected adults… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…